Last reviewed · How we verify
T2-18C3 therapeutic antibody
T2-18C3 therapeutic antibody is a Small molecule drug developed by Janssen Research & Development, LLC. It is currently in Phase 2 development.
At a glance
| Generic name | T2-18C3 therapeutic antibody |
|---|---|
| Sponsor | Janssen Research & Development, LLC |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- T2-18C3 therapeutic antibody CI brief — competitive landscape report
- T2-18C3 therapeutic antibody updates RSS · CI watch RSS
- Janssen Research & Development, LLC portfolio CI
Frequently asked questions about T2-18C3 therapeutic antibody
What is T2-18C3 therapeutic antibody?
T2-18C3 therapeutic antibody is a Small molecule drug developed by Janssen Research & Development, LLC.
Who makes T2-18C3 therapeutic antibody?
T2-18C3 therapeutic antibody is developed by Janssen Research & Development, LLC (see full Janssen Research & Development, LLC pipeline at /company/johnson-johnson).
What development phase is T2-18C3 therapeutic antibody in?
T2-18C3 therapeutic antibody is in Phase 2.